TY - JOUR
T1 - RTOG quality assurance guidelines for clinical trials using hyperthermia for deep-seated malignancy
AU - Sapozink, Michael D.
AU - Corry, Peter M.
AU - Kapp, Daniel S.
AU - Myerson, Robert J.
AU - Dewhirst, M. W.
AU - Emami, B.
AU - Herman, T.
AU - Prionas, S.
AU - Ryan, T.
AU - Samulski, T.
AU - Sapareto, S.
AU - Shrivastava, P.
AU - Stauffer, P.
AU - Waterman, F.
N1 - Funding Information:
pital, University of Southern California School of Medicine, Angeles, CA 90033. Supported by PHS grant CA 2 I66 1 from the NCI. Accepted for publication 9 November 1990.
PY - 1991/5/1
Y1 - 1991/5/1
N2 - Quality assurance has been vague or lacking in many previous hyperthermia trials. Recent publications by the Hyperthermia Physics Center, the Center for Devices and Regulatory Health, and the Radiation Therapy Oncology Group have described general guidelines for quality assurance in equipment reliability and reproducibility, superficial applications, and microwave techniques. The present report details quality assurance factors that are believed to be important for hyperthermia of deep clinical sites, defined as extending as least 3 cm beyond the skin surface. This document will discuss patient and physician factors, as well as thermometric accuracy, assessment of specific absorption rates (SAR), assurance of adequate coverage of tumors by the energy deposition pattern of the treatment device, and recommended documentation of the location, quantity, and frequency of treatment, specifically oriented to deep hyperthermia. The recommendations are structured to facilitate compliance in multiinstitutional trials.
AB - Quality assurance has been vague or lacking in many previous hyperthermia trials. Recent publications by the Hyperthermia Physics Center, the Center for Devices and Regulatory Health, and the Radiation Therapy Oncology Group have described general guidelines for quality assurance in equipment reliability and reproducibility, superficial applications, and microwave techniques. The present report details quality assurance factors that are believed to be important for hyperthermia of deep clinical sites, defined as extending as least 3 cm beyond the skin surface. This document will discuss patient and physician factors, as well as thermometric accuracy, assessment of specific absorption rates (SAR), assurance of adequate coverage of tumors by the energy deposition pattern of the treatment device, and recommended documentation of the location, quantity, and frequency of treatment, specifically oriented to deep hyperthermia. The recommendations are structured to facilitate compliance in multiinstitutional trials.
KW - Clinical trials
KW - Deep hyperthermia
KW - Quality assurance
UR - http://www.scopus.com/inward/record.url?scp=0025906224&partnerID=8YFLogxK
U2 - 10.1016/0360-3016(91)90212-M
DO - 10.1016/0360-3016(91)90212-M
M3 - Article
C2 - 2022513
AN - SCOPUS:0025906224
SN - 0360-3016
VL - 20
SP - 1109
EP - 1115
JO - International journal of radiation oncology, biology, physics
JF - International journal of radiation oncology, biology, physics
IS - 5
ER -